Phenylalanine-based inactivator of akt kinase: Design, synthesis, and biological evaluation

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 462-467

  Nguyen, Thuy ^a   Coover, Robert A ^a   Verghese, Jenson ^a   Moran, Richard G ^a   Ellis, Keith C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AKT kinase; covalent inhibitor; substrate competitive

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CYSTEINE; GLYCOGEN SYNTHASE KINASE 3BETA; PHENYLALANINE DERIVATIVE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

ARTICLE; BINDING SITE; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; ELECTROPHILICITY; ENZYME INACTIVATION; GROWTH INHIBITION; HCT116 CELL LINE; LUNG CANCER CELL LINE; PRIORITY JOURNAL; SYNTHESIS;

EID: 84900388256     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500088x     Document Type: Article

References (26)

1. Fischer, P. M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases Curr. Med. Chem. 2004, 11, 1563-1583
2. Cohen, P. The development and therapeutic potential of protein kinase inhibitors Curr. Opin. Chem. Biol. 1999, 3, 459-465
3. Denessiouk, K. A.; Johnson, M. S. When fold is not important: A common structural framework for adenine and AMP binding in 12 unrelated protein families Proteins: Struct., Funct., Bioinf. 2000, 38, 310-326
4. Traut, T. W. Physiological concentrations of purines and pyrimidines Mol. Cell. Biochem. 1994, 140, 1-22
5. Han, K.-C.; Yeon Kim, S.; Gyeong Yang, E. Recent advances in designing substrate-competitive protein kinase Inhibitors Curr. Pharm. Des. 2012, 18, 2875-2882
6. Pinna, L. A.; Ruzzene, M. How do protein kinases recognize their substrates? Biochim. Biophys. Acta, Mol. Cell Res. 1996, 1314, 191-225
7. Obata, T.; Yaffe, M. B.; Leparc, G. G.; Piro, E. T.; Maegawa, H.; Kashiwagi, A.; Kikkawa, R.; Cantley, L. C. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB J. Biol. Chem. 2000, 275, 36108-36115
8. Luo, Y.; Smith, R. A.; Guan, R.; Liu, X.; Klinghofer, V.; Shen, J.; Hutchins, C.; Richardson, P.; Holzman, T.; Rosenberg, S. H.; Giranda, V. L. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition Biochemistry 2004, 43, 1254-1263
9. Litman, P.; Ohne, O.; Ben-Yaakov, S.; Shemesh-Darvish, L.; Yechezkel, T.; Salitra, Y.; Rubnov, S.; Cohen, I.; Senderowitz, H.; Kidron, D.; Livnah, O.; Levitzki, A.; Livnah, N. A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway Biochemistry 2007, 46, 4716-4724
10. Parang, K.; Cole, P. A. Designing bisubstrate analog inhibitors for protein kinases Pharmacol. Ther. 2002, 93, 145-157
11. Lavogina, D.; Enkvist, E.; Uri, A. Bisubstrate inhibitors of protein kinases: from principle to practical applications ChemMedChem 2010, 5, 23-34
12. Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2010, 2, 949-964
13. Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks J. Med. Chem. 2012, 55, 6243-6262
14. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP Nat. Struct. Mol. Biol. 2002, 9, 940-944
15. Korwar, S.; Nguyen, T.; Ellis, K. C. Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors Bioorg. Med. Chem. Lett. 2014, 24, 271-274
16. Toral-Barza, L.; Zhang, W.-G.; Huang, X.; McDonald, L. A.; Salaski, E. J.; Barbieri, L. R.; Ding, W.-D.; Krishnamurthy, G.; Hu, Y. B.; Lucas, J.; Bernan, V. S.; Cai, P.; Levin, J. I.; Mansour, T. S.; Gibbons, J. J.; Abraham, R. T.; Yu, K. Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines Mol. Cancer Ther. 2007, 6, 3028-3038
17. Salaski, E. J.; Krishnamurthy, G.; Ding, W.-D.; Yu, K.; Insaf, S. S.; Eid, C.; Shim, J.; Levin, J. I.; Tabei, K.; Toral-Barza, L.; Zhang, W.-G.; McDonald, L. A.; Honores, E.; Hanna, C.; Yamashita, A.; Johnson, B.; Li, Z.; Laakso, L.; Powell, D.; Mansour, T. S. Pyranonaphthoquinone lactones: a new class of AKT selective kinase inhibitors alkylate a regulatory loop cysteine J. Med. Chem. 2009, 52, 2181-2184
18. Shearn, C. T.; Fritz, K. S.; Reigan, P.; Petersen, D. R. Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells Biochemistry 2011, 50, 3984-3996
19. Yellaturu, C. R.; Bhanoori, M.; Neeli, I.; Rao, G. N. N -Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A J. Biol. Chem. 2002, 277, 40148-40155
20. Rhodes, N.; Heerding, D. A.; Duckett, D. R.; Eberwein, D. J.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Gilmer, T. M.; Zhang, S.-Y.; Robell, K.; Kahana, J. A.; Geske, R. S.; Kleymenova, E. V.; Choudhry, A. E.; Lai, Z.; Leber, J. D.; Minthorn, E. A.; Strum, S. L.; Wood, E. R.; Huang, P. S.; Copeland, R. A.; Kumar, R. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity Cancer Res. 2008, 68, 2366-2374
21. Lindsley, C. W. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update Curr. Top. Med. Chem. 2010, 10, 458-477
22. Huang, X.; Begley, M.; Morgenstern, K. A.; Gu, Y.; Rose, P.; Zhao, H.; Zhu, X. Crystal structure of an inactive Akt2 kinase domain Structure 2003, 11, 21-30
23. Ikediobi, O. N.; Davies, H.; Bignell, G.; Edkins, S.; Stevens, C.; O'Meara, S.; Santarius, T.; Avis, T.; Barthorpe, S.; Brackenbury, L.; Buck, G.; Butler, A.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray, K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Hunter, C.; Jenkinson, A.; Jones, D.; Kosmidou, V.; Lugg, R.; Menzies, A.; Mironenko, T.; Parker, A.; Perry, J.; Raine, K.; Richardson, D.; Shepherd, R.; Small, A.; Smith, R.; Solomon, H.; Stephens, P.; Teague, J.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.; Reinhold, W.; Weinstein, J. N.; Stratton, M. R.; Futreal, P. A.; Wooster, R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set Mol. Cancer Ther. 2006, 5, 2606-2612
24. Qing-Bai, S.; Chandarlapaty, S.; Qing, Y.; Lobo, J.; Haskell, K. M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 2008, 3, 1-10
25. Kayser-Bricker, K. J.; Glenn, M. P.; Lee, S. H.; Sebti, S. M.; Cheng, J. Q.; Hamilton, A. D. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents Bioorg. Med. Chem. 2009, 17, 1764-1771
26. Pearce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell. Biol. 2010, 11, 9-22